Cobiz Wealth’s CALYPTE BIOMEDICAL CORP NEW HIV Stock Holding History

Cobiz Wealth’s Portfolio HIV Stock Details HIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$0	Hold	595,888	–	–	﹤0.01%	121
2019 Q1	$0	Hold	595,888	–	–	﹤0.01%	129
2018 Q4	$0	Hold	595,888	–	–	﹤0.01%	136
2018 Q3	$0	Hold	595,888	–	–	﹤0.01%	138
2018 Q2	$0	Hold	595,888	–	–	﹤0.01%	136
2018 Q1	$0	Hold	595,888	–	–	﹤0.01%	138
2017 Q4	$0	Hold	595,888	–	–	﹤0.01%	137
2017 Q3	$0	Hold	595,888	–	–	﹤0.01%	133
2017 Q2	$0	Hold	595,888	–	–	﹤0.01%	136
2017 Q1	$0	Hold	595,888	–	–	﹤0.01%	140
2016 Q4	$0	Hold	595,888	–	–	﹤0.01%	139
2016 Q3	$0	Hold	595,888	–	–	﹤0.01%	141
2016 Q2	$0	Hold	595,888	–	–	﹤0.01%	147
2016 Q1	$0	Hold	595,888	–	–	﹤0.01%	148
2015 Q4	$0	Buy	+595,888	New	–	﹤0.01%	150

Cobiz Wealth's HIV Position: Q2 2019 in Review

Cobiz Wealth held its CALYPTE BIOMEDICAL CORP NEW (HIV) position steady in Q2 2019 at 595,888 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #121.

Cobiz Wealth first reported a position in HIV in Q4 2015 and has held it in 15 quarters since. 1 fund tracked by Wall St. Rank holds HIV as of Q2 2019.

Cobiz Wealth held 595,888 shares of CALYPTE BIOMEDICAL CORP NEW worth $0 as of Q2 2019.
Cobiz Wealth left its CALYPTE BIOMEDICAL CORP NEW share count unchanged in Q2 2019.
CALYPTE BIOMEDICAL CORP NEW made up ﹤0.01% of Cobiz Wealth's portfolio in Q2 2019, its #121 holding.
Cobiz Wealth first reported a position in CALYPTE BIOMEDICAL CORP NEW in Q4 2015 and has held it in 15 quarters since.
1 fund tracked by Wall St. Rank held CALYPTE BIOMEDICAL CORP NEW as of Q2 2019.

Based on Cobiz Wealth's 13F filing for Q2 2019, filed 8 Jul 2019.